Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey
This article was originally published in The Pink Sheet Daily
The Swiss drug company has set a goal of generating 60% of sales in emerging markets by 2015.
You may also be interested in...
Swiss pharmaceutical manufacturer Nycomed has acquired rights from specialty pharmaceutical company Biomeks Ilac (Biomeks) to market a portfolio of over ten pharmaceutical products in Turkey
Russia has called for half of all pharmaceuticals in the country to be produced domestically in the next decade, pledging to spend 122.9 billion rubles ($3.97 billion) to get international drug makers to shift drug production to the country and strengthen R&D collaboration
Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma